Last updated: April 23, 2026
Who Supplies FENTANYL-37 (Raw Materials, Intermediates, and Contract Manufacturing)?
No complete, accurate supplier map can be produced from the provided input because “FENTANYL-37” is not a unique, universally indexed drug identifier (INN, USAN, CAS, or a defined registry code). Without an unambiguous chemical identity and code set, supplier lists would risk naming incorrect products, salts, or research compounds, and would not support patent, compliance, or sourcing decisions.
What Supplier Lists Can Be Produced From “FENTANYL-37”?
- A single product name alone is not sufficient to resolve:
- the exact API/salt form (e.g., citrate, hydrochloride, freebase),
- whether it is clinical drug substance vs research reference standard vs intermediate,
- the exact CAS/registry linkage that suppliers use in regulatory and pricing systems,
- the relevant manufacturing class (licensed API manufacturer, compounding lab, standards supplier, or CM process developer).
Where Supplier Identification Normally Comes From (For Actionable Procurement)?
A reliable supplier map is typically anchored to one of the following unambiguous identifiers:
- CAS number for the active ingredient or its salt,
- drug substance monograph identifiers used by regulatory systems,
- structured chemical identity (molecular formula + stereochemistry + salt form),
- patent family coverage that ties “what is being supplied” to a specific claimed compound.
With only “FENTANYL-37,” none of these anchor points can be derived in a way that supports a correct supplier list.
Does “FENTANYL-37” Correspond to a Known Public INN/Drug Substance Entry?
- The term “fentanyl” is well indexed, but “FENTANYL-37” is not a standard public naming convention on its own.
- Supplier rosters are built around regulated, auditable identifiers; ambiguous naming does not produce a deterministic supplier set.
What Supplier Categories Would Normally Apply (If Identity Were Resolved)?
Once identity is unambiguous, the supplier landscape is split into categories that investors and R&D buyers actually use:
- Licensed API manufacturers (drug substance)
- Intermediate producers (key synthetic precursors used upstream)
- Contract manufacturing organizations (CMOs) for finished dosage forms
- Reference standards and analytical suppliers (only if the need is analytical, not drug supply)
A correct answer requires the resolved identity to map into these categories.
Key Takeaways
- “FENTANYL-37” is not a sufficient identifier to produce a complete, accurate supplier list.
- Supplier identification for controlled opioids requires exact API/salt identity tied to regulatory identifiers used by sourcing systems and patent records.
- No actionable supplier map can be generated from the provided input alone without risking incorrect sourcing, compliance, and litigation exposure.
FAQs
-
What does “FENTANYL-37” mean for sourcing?
It does not map to a deterministic, widely indexed drug substance identity by itself.
-
Can I list fentanyl suppliers without the “-37” code?
Not for “FENTANYL-37” specifically; supplier rosters are tied to exact salt/form and registry identifiers.
-
Are API suppliers different from CMOs for fentanyl?
Yes. API suppliers provide drug substance; CMOs typically provide dosage manufacturing and packaging.
-
Do patents help identify suppliers?
Only when the patent claims can be tied to an exact chemical identity and claim coverage for the supplied material.
-
Is there a faster way to generate a supplier list?
Supplier lists require an unambiguous identifier that sourcing and regulatory systems recognize; without that, any list would be non-actionable.
References
[1] World Health Organization. WHO INN Programme: International Nonproprietary Names (INN) for pharmaceutical substances.
[2] U.S. FDA. Drug development and regulatory information (drug substance and labeling identifiers used for regulated sourcing).
[3] EMA. European public assessment resources and substance identifiers used for authorization.
